Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
now we have Jay-Jay as the new CEO on board.
His picture is posted on facebook
KS
hmmm...something is brewing....
leakage....you will go to jail
KS
as already mentioned in today press release
that's the link to the presentation:
View Corporate Presentation
The sky is the limit.
KS
Webcast available now:
Webcast
KS
more news next week:
"If the Merger Agreement is not executed by February 10, 2017, or the Merger is not consummated within six months thereafter (each a “Merger Milestone”), the Company will be required to issue to Bendon 2.5 million shares of common stock; provided, however, that the Company shall not be required to issue Bendon such shares if Bendon’s action(s) or lack thereof has been the principal cause of or resulted in the failure of the parties to achieve a Merger Milestone. "
We should see more news during next week. I will use dips for buys....so please lovely Shorties do your job so I#m able to realise some (long) buys...
KS
Lone Wolf et all,
please read the last PR's again and you see that the "new" shares are already counted in Fridays merger news.... just do the calc.
The "new" shares were part of a December PR so no surprise.
But the company made indeed a mistake because they should have published the finalization of the share offering first. Damn.
KS
daytraders/pizza-traders are out, volume decreasing.
One-digit again eod.
KS
Bill,
good luck to you and SGNL. I sold yesterday and the reason is the following:
- after the merger they will have approx. 19m outstanding shares
- based on that the actual market cap is approx. $300m !!!!!
You should not ignore the market cap please think about that.
KS
Good luck Longs.
Just realized my profits and will enjoy the evening
KS
Made some $k (12) as well. But the power party did not started yet....we need to be patient...6 weeks from now the latest.
More Merger Documents posted on last Friday after the bell....
More News to come over the next couple of days....exciting Christmas days.
Good luck.
KS
News December 1, 2016:
On November 29, 2016, Signal Genetics, Inc. (“Signal”) entered into an Intellectual Property Purchase Agreement (the “IP Purchase Agreement”) with Quest Diagnostics Investments LLC (“Quest”). The consummation and closing of this transaction is subject to, among other things, Signal stockholder approval.
Pursuant to the IP Purchase Agreement, Signal has agreed to sell all of its intellectual property assets relating to the MyPRS test (collectively, the “MyPRS Assets”). As part of the sale of MyPRS Assets, Signal will assign all of its rights, interests and obligations to certain agreements, including, that certain License Agreement effective as of April 1, 2010, made by and between the Board of Trustees of the University of Arkansas acting for and on behalf of the University of Arkansas for Medical Sciences, a public institution of higher education, and Myeloma Health LLC, a Delaware limited liability company, as amended (collectively, the “UAMS License Agreement”). Quest agrees to be bound by the terms, obligations and conditions as a licensee under the UAMS License Agreement pursuant to an assignment and assumption agreement. Signal will also provide to Quest certain information technology, software and firmware related or required for the use of the MyPRS test.
As consideration for the sale of the MyPRS Assets, Quest will pay Signal $825,000, plus an additional $100,000 if Quest exercises the option to require Signal to operate Signal’s lab beyond December 31, 2016 (but not later than January 14, 2017). The closing of this transaction is anticipated to occur as promptly as practicable after Signal obtains stockholder approval and Signal and Quest satisfy all other conditions to closing.
Under the IP Purchase Agreement, Signal is required to indemnify Quest for any breaches of Signal’s representations, warranties, covenants and agreements for their applicable survival period and with respect to any retained liabilities and therefore Signal will have continuing potential liability to Quest following the closing. Quest agrees to indemnify Signal under the IP Purchase Agreement for any breaches of Quest’s representations, warranties or covenants and any assumed liabilities. The IP Purchase Agreement limits Signal’s aggregate liability for indemnification with respect to the breach of certain representations and warranties to $825,000 and $206,250 of this amount for the breach of other representations and warranties and such indemnification is subject to a nuisance provision such that Signal’s indemnification obligations are not triggered unless the aggregate amount of a claim, demand or loss exceeds $41,250.
Until the closing of the sale of the MyPRS Assets, Signal is prohibited from directly or indirectly soliciting, initiating, encouraging, accepting or entertaining any inquiries, offers or proposals from any other person or entity relating to any asset sale or similar transaction involving the MyPRS Assets (with the exception of operating the MyPRS test in the ordinary course of its business).
Under the terms of the IP Purchase Agreement, there are several conditions to closing. Among such conditions, neither Signal nor Quest is obligated to close the sale of the MyPRS Assets if (i) there is a court order or injunction prohibiting the sale of the MyPRS Assets, or (ii) Signal has not obtained stockholder approval for either the sale of the MyPRS Assets or the previously announced Agreement and Plan of Merger and Reorganization dated October 31, 2016, by and among Signal, Signal Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Signal (“Merger Sub”), and Miragen Therapeutics, Inc., a Delaware corporation (the “Merger Agreement”) . Signal’s and Quest’s obligation to close are also contingent upon additional customary closing conditions including, without limitation, the performance of other agreements, covenants and conditions under the IP Purchase Agreement and the execution of certain documents by the parties and delivery of certain closing certificates specified in the IP Purchase Agreement. The closing of the proposed merger contemplated by the Merger Agreement is expected to occur simultaneously with the closing of this transaction.
The IP Purchase Agreement may be terminated due to a number of reasons, including: (i) by mutual written consent of Quest and Signal; (ii) if there has been a material breach, inaccuracy or failure to perform any of the representations, warranties, covenants or agreements of a party as set forth in the IP Purchase Agreement; (iii) the closing of the sale of the MyPRS Assets has not occurred on or before April 30, 2017 (unless agreed to otherwise); (iv) the Merger Agreement has been terminated; (v) any law makes such sale illegal or otherwise prohibited; (vi) a governmental authority issues an order preventing or enjoining the consummation of the transaction; or (vii) a proceeding or investigation seeks material damages in connection with the proposed merger or the sale of the MyPRS Assets.
The preceding summary does not purport to be complete and is qualified in its entirety by reference to the IP Purchase Agreement, a copy of which is included as Exhibit 2.1 to this Current Report on Form 8-K and which is incorporated herein by reference.
Additional Information about the Proposed Merger and Where to Find It
In connection with the previously disclosed proposed merger between Signal Genetics, Inc. and Miragen Therapeutics, Inc., Signal and Miragen intend to file relevant materials with the SEC, including a registration statement on Form S-4 that will contain a proxy statement / prospectus / information statement. Investors and security holders of Signal and Miragen are urged to read these materials when they become available because they will contain important information about Signal, Miragen and the proposed merger and this proposed sale of the MyPRS Assets. The proxy statement / prospectus / information statement and other relevant materials (when they become available), and any other documents filed by Signal with the SEC, may be obtained free of charge at the SEC web site at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by Signal by directing a written request to: Signal Genetics, Inc., 5740 Fleet Street, Carlsbad, CA 92008, Attention: Investor Relations. Investors and security holders are urged to read the proxy statement / prospectus / information statement and the other relevant materials when they become available before making any voting or investment decision with respect to the sale of the MyPRS Assets and the proposed merger.
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities in connection with the proposed merger shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
News from Nov 29:
miRagen Therapeutics Expands Executive Leadership Team
---------------------
Paul Rubin, M.D. Joins as Executive Vice President of Research and Development
BOULDER, CO., November 29, 2016 – miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative microRNA (miRNA)-targeting therapies in disease areas of high unmet medical need, today announced the appointment of Paul Rubin, M.D. to the position of Executive Vice President of Research and Development. Dr. Rubin is a seasoned biopharmaceutical executive with expertise across a range of drug modalities and therapeutic areas. He has been responsible for clinical development programs, which led to regulatory approval of several products during his career with several pharmaceutical and biotechnology companies.
“Paul brings an impressive breadth and depth of experience in drug discovery and development to our team.” said William S. Marshall, Ph.D., President and Chief Executive Officer of miRagen. “I’m excited to welcome him to the miRagen team and look forward to working together to advance our product candidate portfolio.”
“I welcome the opportunity to contribute to the advancement of miRagen’s platform of RNA-based therapeutics”, said Dr. Rubin. “I am particularly excited to join the team presently managing miRagen’s two lead candidates, MRG-106 for the treatment of certain cancers, and MRG-201 for the treatment of pathological fibrosis as they continue to advance these products in clinical trials.”
Prior to joining miRagen, Dr. Rubin held various roles at Xoma Corporation from June 2011 to November 2016, most recently serving as its Chief Medical Officer, and Senior Vice President of Research and Development. Prior to joining Xoma Corporation, Dr. Rubin was the Chief Medical Officer at Funxional Therapeutics Ltd. from February 2011 to June 2011, the Chief Executive Officer of Resolvyx Pharmaceuticals, Inc. from 2007 to 2009 and the President and Chief Executive Officer of Critical Therapeutics, Inc. from 2002 to 2007.
From 1996 to 2002, Dr. Rubin held various roles with Sepracor, Inc., where he served as Senior Vice President, Development, and later as Executive Vice President, Research & Development. While at Sepracor he led the development of Sepracor’s internally developed approved products including Xopenex ® , Lunesta ® , Xopenex HFA ® and Brovana ® .
From 1993 to 1996, Paul held senior level positions at Glaxo-Wellcome Pharmaceuticals, including Vice President of Worldwide Clinical Pharmacology and Early Clinical Development. From 1987 to 1993, Dr. Rubin held various roles with Abbott Laboratories, including as Vice President, Immunology and Endocrinology, where he successfully advanced zileuton, the first 5-lipoxygenase inhibitor, from discovery to approval for the treatment of asthma.
Dr. Rubin received a B.A. from Occidental College and an M.D. from Rush Medical College. He completed his training in internal medicine at the University of Wisconsin.
Woooow
Based on the latest filings from last Friday the overall
cash position after receiving the full awards from SIGA
- $83.7m are still pending - and after tax (using full NOL as a tax reduction) should be around $205m.
Using a number of 66,4m shares the Cash per share is $3.09
what means a dividend (90% of Cash, see filings) of $2,78 per share.
Plus there is a running business as well.
BUY !!!
thats absolutely the right math.....enjoy the ride.
close around $1 should be possible today....lets wait and see.
Very, very happy to hear that
Lets see what today's conf call will bring on the table,
it is scheduled for later today.
we should see some movement today:
from SIGA's latest FORM 8-K:
"Item 8.01 Other Events.
As previously disclosed on August 18, 2016, the United States Bankruptcy Court for the Southern District of New York approved a Joint Motion of Reorganized Debtor and PharmAthene, Inc. to Amend Debtor’s Third Amended Chapter 11 Plan to Extend PharmAthene Allowed Claim Treatment Date, which extended the deadline for SIGA Technologies, Inc. (“SIGA”) to satisfy the previously disclosed judgment (the “PharmAthene Judgment”) owed to PharmAthene, Inc . (“PharmAthene”) from October 19, 2016 to November 30, 2016, conditioned on SIGA’s payment to PharmAthene of $100 million on or prior to October 19, 2016, which payment would be applied against the PharmAthene Judgment. On October 5, 2016, SIGA completed payment to PharmAthene of such $100 million amount, thereby satisfying the required condition and extending the deadline for satisfaction of the remainder of the PharmAthene Judgment to November 30, 2016. "
New Quarterly Report out!
HTIC — Quarterly Report
Hitec Financial Statements 8-31-16
Published: Oct 03, 2016
Period End: Aug 31, 2016
KS
"During May 2016 the Company received a $0.9 million interest payment from SIGA for the period from April 12 to April 30, 2016"
COOL
KS
SIGA Announces That Delaware Supreme Court Affirms Court of Chancery Opinion
SIGA Technologies, Inc. a company specializing in the commercialization of solutions for serious unmet medical needs and biothreats, today announced that the Delaware Supreme Court affirmed the prior Court of Chancery Opinion in which the court awarded PharmAthene, Inc. approximately $195 million, including pre-judgment interest up to January 15, 2015.
Dr. Eric A. Rose, SIGA's Chairman and Chief Executive Officer, said, "We are surprised and very disappointed by this ruling. Nevertheless, in anticipation of a ruling by the Delaware Supreme Court, on December 15, 2015, SIGA filed a plan of reorganization ("the Plan") in its pending case under chapter 11 of the United States Bankruptcy Code. The Plan, among other things, affords SIGA with certain options to satisfy PharmAthene's claim. The Plan is supported by the Official Committee of Unsecured Creditors appointed in SIGA's chapter 11 case, of which PharmAthene is one of two members. We remain absolutely committed to continuing to produce and deliver our smallpox antiviral drug, Tecovirimat, to the US Government's Biomedical Advanced Research and Development Authority, pursuing FDA approval and operating our business."
Payday !!!
$ 12,124,000 cash on hand (as of SEP-30, 2015)
10,635,454 shares outstanding (as of SEP-30, 2015)
=> $1.13 cash per share
=> current placement of equity has been completed !!!
=> UNDERVALUED
KS
Company should release at least a PR explaining ticker change and timeframe. Fools.
$HTIC
So far HTIC reached the following milestones
- audited filings
- name change
- yield sign gone, HTIC is "current"
That's the main reason for the ongoing re-evaluation.
But more news will follow soon, read earlier postings,
so this is just the starting point.
$HTIC future is bright....
KS
Expecting breaking news next week.
Place your bet and fasten your seat belt,
this is a potential 10 bagger.
KS
Financial statements 8-31-15 released on Oct 22nd.
link to financial statement
KS
Volume increasing....Good luck, should see $1,60 today.
from todays news: "Together with the PPO agreement we announced earlier this year and our other payor relationships with Medicare and Blue Cross Blue Shield of Arkansas, the covered lives within our universe has increased to over 93 million patients in the United States."
really G * R * E * A * T news
VOLUME....something is brewing.
10Q is out now:
link to 10Q
KS
Equity offering knocking the door: the last offering in Feb 15 was a great success for all of us traders...this will happen now again.
Guys, place your bets.
KS
Signal Genetics (NASDAQ:SGNL) Files S-3 Statement - Signal Genetics has also filed a S-3 statement, which contains two prospectuses. The base prospectus covers the offering, issuance and sale of up to $50 million in the aggregate of the securities identified in a statement from time to time in one or more offerings. The sales agreement prospectus covers the offering, issuance and sale by SGNL of up to a maximum aggregate offering price of $4.45 million of its common stock that may be issued and sold under a sales agreement with Cantor Fitzgerald.
Signal Genetics Announces Master Service Agreement
CARLSBAD, Calif., June 30, 2015 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (NASDAQ:SGNL) (Signal), a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced the signing of a Master Service Agreement (MSA) with a leading pharmaceutical company. Under the MSA, Signal's proprietary MyPRS® genetic test will be run across multiple clinical trials in connection with the development of novel treatments for patients with multiple myeloma.
Signal and the pharmaceutical company have triggered the first of four studies as part of the MSA. Under the agreement, MyPRS® will help inform patterns of response to novel therapy regimens with the aim of enabling physicians to better manage multiple myeloma patients based on their specific genetic profile.
Michael Cerio, SVP of Commercial Strategy and Business Development, commented, "This services agreement with a leading pharmaceutical company is a significant achievement for Signal, and validates the potential of our technology to impact therapy decisions in multiple myeloma. We believe this agreement demonstrates that the pharmaceutical industry recognizes the value of MyPRS® as part of the genetic testing armament in cancer. Developing a pipeline of pharmaceutical company relationships is a key objective for Signal, and we plan to pursue additional clinical trial service agreements with multiple clients as part of our overarching commercial strategy going forward."
NEWS !!!
Thanks for your DD. But anticipated filing date is just 5 calendar days away.